Pfizer Inc (PFE-N)

Believes stock is bottoming out right now. New products are going to present opportunity. ~5.5% also good. 

They pay over a 6% dividend and trades at 9x PE. A wonderful story here. Will grow at a realistic 3-8% as you collect that dividend.

It is down 60% from its peak and trading at 10X forward earnings with a 6% dividend yield, It took the windfall cash from the Covid vaccines, etc. and re-invested in new growth areas such as cancer, diabetic and weight loss treatments/ drugs., It is out of favour and there is potential for growth.
Buy 11  Hold 15  Sell 0

It reports Wednesday. He wants to hear how their purchase of Seagan has impacted the numbers.

No, though it might bounce and you can collect their dividend.

Industry, overall, is fairly mature. Challenging to get drugs approved. Pharma companies are struggling to grow, dealing with patent cliffs. Flipside is generating good cashflows. Very attractive for income, but don't own it for share price performance, since growth is challenged. Yield is 6.5%, safe.

A CDR lets you bypass any U.S. estate probate tax issues. He owned Pfizer during Covid. Shares have slid since then, below its 200-day moving average. Could be some value at 12x forward PE, but won't touch it.

A very contrarian pick. Why now? Company's pivoting from Covid to cancer. Unfortunately, cancer is a huge market with 1 in 3 being diagnosed. Very strong lineup of potential new blockbuster drugs, management confidence is high on them. Market underappreciates it. Estimated to grow earnings 14%. Trades at 10x, with nice yield of 5.96%.

Near the bottom, won't go much lower. Not if it will work, but when. You get a nice dividend. Tomorrow's winner.

Starting to look at it. Just made an acquisition. Growth rates starting to accelerate.

Currently - stock is at a low price which presents a good buying opportunity. Excellent R&D department. Lots of products coming to the market. Dividend is able to help returns too. Obesity drugs also adding to bottom line (trendy product). 

Hurting. He considers it in a downtrend, lower highs and lower lows, until proven otherwise. Proof that it's over is you start to see consolidation, little zig-zags on the chart. Could start soon, but hasn't yet.

Great company, Covid saviour. Ran up on that, now falling off. Back to more normalized levels. Not his first choice. He owns MRK.

Would recommend buying even with share price weakness. Does not believe market is pricing fairly. Dividend is safe. 

He was looking at it the other day. Trading where it was 30 years ago, despite a slew of acquisitions allowing it to tread water. Big dividend. Bought back shares. Pharma industry in general has been tough for 30 years. FDA has been tougher. Drugs coming out are more narrow-niche. Drug prices are under pressure globally. 

They're having a hangover, post-Covid, after selling vaccines, but those sales have plunged. But at $50 billion in sales, PFE remains a global pharma leader. Pays a 6% dividend. Shares are close to bottoming. Trades at only 12x PE vs. peers like Eli Lily at 70-80x.